Rationale Nicotinic acetylcholine receptor (nAChR) agonists, partial agonists, and antagonists have antidepressant-like effects in rodents and reduce symptoms of depression in humans. Objectives The study determined whether the antidepressantlike effect of the nAChR β2* partial agonist sazetidine-A (sazetidine) in the forced swim test was due to activation or desensitization of β2* nAChRs. The study also determined if sazetidine's behavioral responses in the forced swim test corresponded to β2* nAChRs receptor occupancy and drug bioavailability. Results Acute antidepressant-like effects in the forced swim test were seen with sazetidine and the full β2* agonist 5-I-A8350 (BALB/cJ mice) and the less selective β2* partial agonist varenicline in C57BL/6J but not BALB/cJ mice. The role of β2* nAChRs was confirmed by results showing: (1) reversal of sazetidine's antidepressant-like effects in the forced swim test by nAChR antagonists mecamylamine and dihydro-β-erythroidine; (2) absence of sazetidine's effect in mice lacking the β2 subunit of the nAChR; and (3) a high correspondence between behaviorally active doses of sazetidine and β2* receptor occupancy. β2* receptor occupancy following acute sazetidine, varenicline, and 5-I-A8350 lasted beyond the duration of action in the forced swim test. Sazetidine's long lasting receptor occupancy did not diminish behavioral efficacy in the forced swim test following repeated dosing. Conclusions Results demonstrate that activation of a small population of β2* nAChRs (10-40%) is sufficient to elicit sazetidine's antidepressant-like actions without producing tolerance and suggest that ligands that activate β2* nAChRs would be promising targets for the development of a new class of antidepressant.
Introduction
Nicotinic acetylcholine receptor (nAChR) ligands may represent a novel class of therapeutic agents for treating depression (Shytle et al. 2002) . There is particularly strong support for the role of β2* nAChRs (asterisk indicates assembly with other nAChR subunits) in mediating the antidepressant-like response of nAChR ligands as well as traditional antidepressants. β2 subunit knockout mice (Picciotto et al. 1995) showed no behavioral antidepressant response to either mecamylamine (Rabenstein et al. 2006) or the tricyclic antidepressant amitriptyline and lacked the expected increase in hippocampal cell proliferation by amitriptyline (Caldarone et al. 2004) . Acute treatment with the α4β2* agonist A-85380 was effective in the mouse forced swim test (Buckley et al. 2004) , and subchronic treatment with the α4β2* agonist SIB-1508Y produced an antidepressant-like response in the learned helplessness model (Ferguson et al. 2000) . Administration of the α4β2* partial agonists varenicline (Rollema et al. 2009 ), cytisine , and TC-1734 (Gatto et al. 2004 ) produced antidepressant-like activity in the forced swim test, and NS3956 enhanced the effects of citalopram and reboxetine in the forced swim test (Andreasen et al. 2010) . Gene expression profile studies in an animal model of depression also support the role of β2* receptors in depressive responses. Social defeat, which induces depression-like behavior in rodents (Kudryavtseva et al. 1991) , produced a robust increase in expression of the β2* nAChR subunit in the brain (Kroes et al. 2007 ). Taken together, these studies suggest that ligands that target β2* nAChRs would be effective antidepressants.
Although the role of β2* receptors in mediating the antidepressant response of nAChR ligands is well supported, it is unclear whether nAChR activation, desensitization, or some combination of both is essential ). We used sazetidine-A (sazetidine/ AMOP-H-OH) (Kozikowski et al. 2009; Xiao et al. 2006; Zwart et al. 2008 ), a β2* partial agonist and desensitizer that showed robust antidepressant-like properties in the forced swim test (Kozikowski et al. 2009; Turner et al. 2010) to address these questions. We first confirmed the role of β2* nAChRs in mediating sazetidine's antidepressantlike effects in the forced swim test. This was carried out by determining if the effects of sazetidine in the forced swim test were absent in the β2 subunit knockout mice and whether there was a correspondence between behaviorally active doses of sazetidine and β2* receptor occupancy. Next, we confirmed whether sazetidine acted primarily via nAChR activation or desensitization, by determining if the antidepressant-like effects of sazetidine could be blocked by administration of nAChR antagonists, and if an acute dose of sazetidine would desensitize the nAChRs, so the subsequent doses would not produce antidepressant-like effects in the forced swim test. Additional studies compared sazetidine's behavioral effects and β2* receptor occupancy to those of the well-characterized α4β2* full agonist 5-I-A85380 and the α4β2* partial agonist varenicline.
Methods

Animals
BALB/cJ (BALB) and C57BL/6J (C57) male mice (approximately 2-4 months of age at the time of behavioral testing) were obtained from Jackson Laboratory (Bar Harbor, ME, USA). Mice were housed four to a cage in a colony room on a 12 h light-dark cycle maintained at 22°C (±3) with a relative humidity between 30% and 70%. β2 subunit knockout (KO), heterozygous (HET), and wild-type (WT) littermate male mice (between 4 and 13 months of age at testing) were bred more than 30 generations on to a C57 background. All animal experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council 2010) and the PsychoGenics and Yale University Animal Care and Use Committees.
Drug treatments
Sazetidine-A 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol was synthesized according to published methods (Kozikowski et al. 2009 ). Mecamylamine hydrochloride, methyllycaconitine citrate hydrate (MLA), dihydro-betaerythroidine hydrobromide (DHβE), and desipramine hydrochloride were purchased from Sigma (St. Louis, MO, USA), sertraline hydrochloride from Toronto Research Chemicals (Ontario, Canada), varenicline tartrate from Allichem (Savage, MD, USA), and 5-Iodo-A-85380 (5-I-A85380) dihydrochloride from Tocris Bioscience (Ellisville, MO, USA). All drugs were dissolved in either saline, phosphate-buffered saline, or injectable water and injected intraperitoneally (i.p.) in a volume of 10 ml/kg. All doses are expressed as salt except for varenicline, which is expressed as the free base.
5-I-A85380, varenicline, and sazetidine in the mouse forced swim test
Procedures were based on methods initially described (Porsolt et al. 1977 ) and in our laboratory (Kozikowski et al. 2009 ) validating acute antidepressant responsiveness in mice. Mice were placed individually into clear glass cylinders (i.e., 15 cm tall x 10 cm wide, 1 L beakers) containing 23±1°C water 12 cm deep (approximately 800 ml). The time the animal spent immobile was recorded over a 6-min trial. Immobility was described as the postural position of floating in the water.
The antidepressant-like effects of the α4β2* full agonist 5-I-A85380, and the α4β2* partial agonists varenicline and sazetidine, were compared in the forced swim test (see Fig. 1 for structures) . 5-I-A85380 and sazetidine were tested in the BALB strain, and varenicline was tested in both BALB and C57 mice. Mice received a 30-min pretreatment with either 5-I-A85380 (0, 0.03, 0.1, and 0.3 mg/kg; n=8/group), varenicline (0, 0.3, 1, or 3 mg/kg; n=9-10/group, BALB; n=10/group, C57), or sazetidine (0, 0.3, 1, 3, or 10 mg/kg; n=9-10/group). Positive controls were sertraline (10 or 20 mg/kg) in BALB mice and desipramine (20 mg/kg) in C57 mice.
Sazetidine: ex vivo binding to assess receptor occupancy of β2* nAChRs Next, we determined whether occupancy of β2 nAChR binding sites in the brain corresponded with behavioral efficacy of sazetidine in the forced swim test. Sazetidine (0.3, 1, and 3 mg/kg) or vehicle was administered 30 min before brain collection (the same time point as forced swim testing) for analysis of receptor occupancy of the thalamus (n=3/group). An additional group of mice was administered sazetidine (3 mg/kg) or vehicle 30 min before brain collection for analysis of receptor occupancy in various brain regions [thalamus, amygdala, prefrontal cortex (PFC) , and the dorsal striatum] (n=4/group).
Mouse brains were sectioned with a Leica CM3050S cryostat (Leica, Germany). Twenty-micrometer sections were mounted on a poly-lysine coated slide and instantly dried with a slide warmer. Six sections were taken in total with adjacent sections 300 μm apart.
For [ 3 H]-cytisine binding, matching sections from vehicle and drug treated mice were incubated with 1 nM [ 3 H]-Cytisine (Perkin Elmer, CT) on ice for 30 min in a binding buffer consisting of 50 mM Tris-HCl pH 7.4, 120 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , and 2.5 mM CaCl 2 . After incubating, the slides were washed twice (1 min each wash) in ice cold binding buffer, dipped in ice cold deionized water, and dried under a stream of cool air. Non-specific binding was not performed due to the high specific binding for the ligand (98%). For beta-imaging, aluminum tapes were placed on the back of dried slides, the slides were loaded into the beta-imager 2000 (Biospace Lab, FR), and the images of the brains slices were acquired overnight according to published methods (Langlois et al. 2001) . For data quantification and receptor occupancy calculation, the intensity of [ 3 H]-cytisine binding from vehicle or drug-treated mice was quantified with betaversion+software (Biospace Lab, FR).
Assessment of the role of β2* nAChRs in the antidepressant-like effects of sazetidine in the forced swim test
To confirm the role of β2* nAChRs in mediating the behavioral effects of sazetidine in the forced swim test, both pharmacological antagonists and genetic approaches were used. For pharmacological antagonist testing, BALB mice were administered the non-selective, noncompetitive nAChR antagonist mecamylamine (1 mg/kg; n=10/group), the competitive α4β2/α4β4 nAChR antagonist dihydro-beta-erythroidine (DHβE; 3 mg/kg) (n=9-10/group) (Harvey et al. 1996) , or the α7 antagonist methyllycaconitine (MLA; 10 mg/kg) (n=9-10/group), 5 min before treatment with sazetidine (3 mg/kg for mecamylamine study and 1 mg/kg for DHβE and MLA studies). To confirm pharmacological results, effects of sazetidine (1 mg/kg, 30 min pretreatment) in the forced swim test were compared in the KO, HET, and WT littermates of mice lacking the β2 subunit of the nAChR (n=5-8/group).
Sazetidine: comparison of duration of action in the forced swim test, β2* ex vivo receptor occupancy, and drug levels in plasma and brain
The duration of action of sazetidine in the forced swim test was measured to determine if the time course corresponded with sazetidine's pharmacokinetic and receptor occupancy profile. BALB mice were tested in the forced swim assay following a 2, 3, 4, or 5 h pretreatment with either sazetidine (1 mg/kg) or vehicle (vehicle, n=18; 2, 3, 4 h pretreatment, n=10/group; 5 h pretreatment, n=6).
To determine the nAChR occupancy profile, BALB mice were treated with sazetidine (1 or 3 mg/kg), and brains were collected 0.25, 4, 8, and 24 h following drug administration for ex vivo receptor occupancy studies (n=5-6/group).
To determine the pharmacokinetic profile of sazetidine, BALB mice were treated with sazetidine (1 and 3 mg/kg) for 0.25, 0.5, 1, 2, or 4 h (n=3/group) before collection of trunk blood and brain samples. Concentrations of sazetidine were determined by reverse phase high-performance liquid chromatography (HPLC) (Enthalpy Analytical Inc, Durham, NC, USA). The effects of a well-characterized α4β2* nAChR partial agonist (varenicline) and full agonist (5-I-A85380) were tested to determine the duration of action in the forced swim and the duration of receptor occupancy. BALB mice were administered either 5-I-A85380 (0.3 mg/kg) or vehicle (n=10-12/group), and C57 mice were administered either varenicline (0.3 mg/kg) or vehicle 0.5, 4, or 8 h before forced swim testing (n=8-12/group). Brains were collected for ex vivo receptor occupancy studies under the same conditions from a separate set of mice for 5-I-A85380 (0.3 mg/kg) in BALB mice (n=5/group) and varenicline (0.3 mg/kg) in C57 mice (n=4-5/group).
Assessment of behavior in the forced swim and locomotor activity tests following repeated administration of sazetidine
To determine whether repeated administration of sazetidine would produce behavioral tolerance in the forced swim test, BALB mice were administered sazetidine (1 or 3 mg/kg), sertraline (10 mg/kg), or vehicle once a day for 13 days. A final injection on the 14th day was given 30 min before forced swim testing (n=9-10/group). "Acute" tolerance to sazetidine was determined by administering a second dose of sazetidine (3 mg/kg) or vehicle, 30 min before behavioral testing (n=9-10/group), to animals pretreated for 8 h with the 3 mg/kg of sazetidine or vehicle. An 8-h pretreatment was chosen because high receptor occupancy did not translate into behavioral efficacy in the forced swim test at this time point. A subset of brains (n= 3/group) was collected immediately following the "acute tolerance" testing to access receptor occupancy.
Locomotor activity was assessed to determine if chronic administration of sazetidine altered locomotor activity. Locomotor activity was measured in Plexiglas square chambers (27.3×27.3×20.3 cm; Med Associates Inc., St Albans, VT, USA) surrounded by infrared photobeams. Mice were administered sazetidine (1 or 3 mg/kg) or vehicle for 2 weeks. Approximately 1 day after the last injection, mice were placed into the open field, and locomotor activity was measured for 30 min. Mice were then administered either vehicle or sazetidine (1 or 3 mg/kg), and activity was measured for an additional 30 min (n=11-12/group).
Statistical analyses
All data were analyzed with analysis of variance (ANOVA) with dependent variables as follows: forced swim test, total time immobile (sec/6 min), locomotor activity, distance traveled (cm/30 min) pre-and post-drug administration, receptor occupancy, and percent occupancy. All significant main effects and interactions were followed up with the Student-Newman-Keuls post hoc test. An effect was considered significant if p<0.05 (Statview for Windows, Version 5.0). (Fig. 2b ). Varenicline reduced immobility in the C57 strain [one-way ANOVA, F(3,36)=53.9, p<0.0001] with significant reductions seen at all doses tested (0.3, 1, and 3 mg/kg), confirming the antidepressant-like activity in this strain (Rollema et al. 2009 ). Desipramine (20 mg/kg) produced the expected reduction in immobility in the C57 strain [one-way ANOVA, F(1,18)=79.0, p<0.0001] (Fig. 2c) . In addition to the partial agonists action at α4β2* receptors, varenicline is a full agonist at α7 receptors (Mihalak et al. 2006) , an effect that could explain the strain differences in the response to varenicline in the forced swim test.
Results
5-I-
Sazetidine produced high levels of β2* receptor occupancy that corresponded to potency in the mouse forced swim test Sazetidine dose dependently reduced immobility in BALB mice [one-way ANOVA, F(4,44) = 23.6, p < 0.0001] (Fig. 3a) , with significant reductions seen at 1, 3, and 10 mg/kg, but not at 0.3 mg/kg. The magnitude of the antidepressant-like response of the active doses of sazetidine was similar to that produced by sertraline [20 mg/kg; one-way ANOVA, F(1,17)=20.8, p<0.001].
An ex vivo receptor occupancy study determined if the behavioral potency of sazetidine corresponded to the specific binding at β2* receptors. [
3 H]-Cytisine (1 nM) showed no specific binding in sections from the thalamus, amygdala, prefrontal cortex, or striatum of the β2 KO mice, confirming that under conditions used in this report, expression pattern obtained in the WT animal is due to a selective binding of [ 3 H]-cytisine to the β2* receptors (Fig. 3b) . The K i value for sazetidine binding (displacement
of [
3 H]-cytisine) to β2* nAChRs in the thalamus of WT mice was 0.2 nM (data not shown).
At 30 min after drug administration, a dose of sazetidine that was inactive in the forced swim test (0.3 mg/kg) resulted in very low levels of β2* nAChRs occupancy (∼10%). In contrast, doses of sazetidine that produced efficacy in forced swim resulted in higher levels of receptor occupancy (∼40% at 1 mg/kg; ∼90% at 3 mg/kg). ANOVA confirmed that receptor occupancy varied according to dose [one-way ANOVA, F(3,8)=82.2, p<0.0001] with post hoc tests showing that the 0.3 mg/kg dose was not different from vehicle but that all other doses of sazetidine were significantly different from each other and from vehicle (Fig. 3c) . Analysis of receptor occupancy 30 min following a 3 mg/kg dose of sazetidine showed no differences between occupancy in the thalamus, amygdala, prefrontal cortex, or striatum. Although ANOVA showed a trend for differences between occupancy in various brain regions [one-way ANOVA, F(3,12)=3.3, p=0.057], post hoc tests did not reveal any differences in occupancy in various brain regions (Fig. 3d) . Therefore, the thalamus was used for quantification of receptor occupancy for all subsequent studies.
Sazetidine's antidepressant-like effects in the forced swim test require β2* nAChRs Mecamylamine completely blocked the antidepressant-like effect of sazetidine [two-way ANOVA: sazetidine×meca-mylamine interaction, F(1,36)=15.4, p<0.001]. Sazetidinetreated mice spent less time immobile compared to vehicletreated mice, but mice pretreated with mecamylamine were indistinguishable from vehicle treated mice (Fig. 4a ). These results demonstrate the nAChRs mediate the behavioral effects of sazetidine in the forced swim test.
MLA did not block the antidepressant-like effect of sazetidine. Sazetidine reduced immobility in mice both with and without MLA pretreatment [main effect of sazetidine treatment, two-way ANOVA, F(1,35)=121.7, p<0.0001]. Although the sazetidine × MLA interaction [two-way ANOVA, F(1,35)=3.9, p=0.057] approached significance, post hoc tests showed that mice treated with MLA and sazetidine were not statistically different from mice treated with sazetidine alone (Fig. 4b) . These results suggest that α7 nAChRs are not involved in the behavioral effects of sazetidine in the forced swim test and are consistent with in vitro displacement binding data showing that sazetidine at a concentration of 10 μM does not displace [
125 H] alpha-bungarotoxin binding [Cerep, catalog no.0567 and (Sharples et al. 2000) ].
DHβE completely blocked the antidepressant-like effect of sazetidine (sazetidine ×DHβE interaction [two-way ANOVA: F(1,34) = 37.5, p < 0.0001]. Sazetidine-treated mice spent less time immobile compared to vehicletreated mice, but mice that were pretreated with DHβE were indistinguishable from vehicle-treated mice (Fig. 4c) . These results suggest that heteromeric nAChRs mediate the behavioral effects of sazetidine in the forced swim test.
β2 subunit KO mice did not respond to sazetidine in the forced swim ([two-way ANOVA: genotype×drug (Fig. 4d) . These results confirm the role of β2* nAChRs in mediating the behavioral effects of sazetidine in the forced swim test.
Sazetidine showed a dissociation between duration of action in the mouse forced swim test, pharmacokinetic profile, and β2* receptor occupancy in the brain Sazetidine was long acting in the forced swim test with behavioral activity observed up to 4 h after pretreatment [one-way ANOVA, F(4,49)=50.5, p<0.0001] (pretreatment time did not influence immobility time in vehicle-treated mice so all vehicle mice were combined for analyses). Sazetidine (1 mg/kg) significantly reduced immobility following 2, 3, and 4 h but not after 5 h pretreatment (Fig. 5a ). The effects of sazetidine at a 3 mg/kg dose are also present at 4 h (data not shown) and completely absent after 8 h pretreatment (Fig. 7c ).
Plasma and brain exposure levels of sazetidine did not correspond to the duration of action in the forced swim test. Although plasma levels showed a dose-response relationship 15 min after administration (∼20 ng/ml at 1 mg/kg and ∼60 ng/ml at 3 mg/kg), sazetidine was nearly nondetectable by 30 min after administration (Fig. 5b ). Brain levels of sazetidine reached low exposure levels 15 min after administration (∼3 ng/g at 1 mg/kg and ∼10 ng/g at 3 mg/kg) and were at or below detection level at the later time points (Fig. 5c) .
Because duration of action of sazetidine in the forced swim test did not correspond to its plasma and brain exposure levels, ex vivo β2* receptor occupancy in the thalamus was measured to determine if the time course of behavioral efficacy of sazetidine could be explained by occupancy of sazetidine at β2* receptors. Results showed a very slow dissociation rate of sazetidine from β2* receptors, with receptor occupancy varying according to β2 Heterozygote β2 Knockout Fig. 4 The antidepressant-like activity of sazetidine is mediated by β2* receptors. Although sazetidine was not behaviorally active in the forced swim test after 8 and 24 h post-dosing, the receptor occupancy rates remained high (∼60% and ∼80% at 1 mg/kg and 3 mg/kg respectively 8 h post administration; ∼60% for the 3 mg/kg 24 h post administration; Fig. 5d ). The high receptor occupancy (80%) achieved by 3 mg/kg of sazetidine at 8 h postadministration, however, did not translate to efficacy in the forced swim test (Fig. 7c) .
Varenicline and 5-I-A85380 showed a dissociation between duration of action in the mouse forced swim test and β2* receptor occupancy in the brain Sazetidine's receptor occupancy time course was compared with varenicline and 5-I-A85380, a compound with a core structure similar to sazetidine, lacking sazetidine's side chain (Fig. 1) . Doses of 5-I-A85380 (0.3 mg/kg) ( Fig. 2a) and varenicline (0.3 mg/kg) (Fig. 2c ) that were behaviorally active in the forced swim test were administered to mice and brains were harvested 0.5, 4, 8, and 24 h after drug administration. Results showed that both 5-I-A85380 (Fig. 6a) and varenicline (Fig. 6b ) produced high levels of receptor occupancy at β2* receptors that varied across time [one-way ANOVA: 5-I-A85380, F(3,16)=258.7, p< 0.0001; varenicline, F(3,15)=58.8, p<0.0001). Similar to sazetidine, both compounds produced very high levels of receptor occupancy at 30 min after drug administration, but unlike sazetidine, levels of occupancy diminished with each time point over 24 h. Both varenicline and 5-I-A85380 appeared to follow single site, one phase dissociation kinetics with the dissociation half-life of varenicline ∼5.4 h and 5-I-A85380 ∼3.4 h. The short dissociation half-life of 5-I-A85380 supports the hypothesis that the structural side chain of sazetidine likely contributes to its long receptor occupancy.
The antidepressant-like effect of 5-I-A85380 [one-way ANOVA: F(3,38)=69.0, p<0.0001) and varenicline (oneway ANOVA: F(3,36)=7.0, p<0.001)] (pretreatment time did not influence immobility time in vehicle treated mice so all vehicle mice were combined analyses), varied across time, with activity for both compounds seen at 0.5 h but not at 4 or 8 h after treatment. Like sazetidine, the duration of action of 5-I-A85380 (Fig. 6c) and varenicline (Fig. 6d) was short (0.5 h), in contrast to the receptor occupancy profile, which showed high levels of binding (∼70%) up to 4 h after treatment. These results suggest that prolonged binding at β2* receptors, extending beyond the duration of action in the forced swim test, may be a common feature of nicotinic agonists and partial agonists.
Sazetidine did not produce tolerance in the forced swim test
To determine if the prolonged binding of nAChR ligands would inhibit behavioral activity with repeated administration, we tested whether sazetidine would produce tolerance following chronic administration or following two acute injections spaced 7.5 h apart. Sazetidine did not produce tolerance following chronic administration for 2 weeks. 52.9, p<0.0001] at both 1 and 3 mg/kg doses following chronic administration, to the same extent as acute dosing. Sertraline also produced the expected reduction in immobility following chronic treatment [one-way ANOVA, F(1,18)= 12.5, p<0.01] (Fig. 7a) .
Chronic treatment with sazetidine did not affect baseline locomotor activity [one-way ANOVA, F(2,32)=1.88, p= 0.170], but an acute challenge decreased locomotor activity [one-way ANOVA, F(2,32)=6.70, p<0.01]. Post hoc tests showed that the acute administration of both 1 and 3 mg/kg doses of sazetidine produced a small decrease in locomotion (Fig. 7b) .
Sazetidine also did not produce acute tolerance with two doses administered at 7.5 h interval [two-way ANOVA: significant main effect of the second drug treatment, F (1,35)=101.1, p<0.0001], with no significant main effect of the first treatment or interaction between the two treatments. Post hoc tests confirmed that a second treatment of sazetidine reduced immobility equally in mice that received vehicle or sazetidine as the first treatment (Fig. 7c) . Immediately following forced swim testing, a subset of brains was collected for assessment of receptor occupancy. Results showed that receptor occupancy varied according to sazetidine treatment [one-way ANOVA, F (2,6)=7.0, p<0.05]. Post hoc tests showed that the level of receptor occupancy was increased in mice that received both the 8 h pretreatment and the challenge dose of sazetidine 30 min before forced swim testing (92% β2* nAChR occupancy), compared to mice that just received the 8 h pretreatment with sazetidine (74% β2* nAChR occupancy; Fig. 7d ).
Discussion
Sazetidine showed an acute antidepressant-like effect in BALB mice consistent with previous reports of activity in the forced swim test in both C57 (Kozikowski et al. 2009 ) and 129SvJ;C57BL/6JF1 hybrid mice (Turner et al. 2010) . Sazetidine also exhibited an antidepressant-like profile following acute administration in the tail suspension test and following chronic, but not acute, treatment in the (Turner et al. 2010) , consistent with the efficacy profile of traditional antidepressants (Dulawa and Hen 2005) . Sazetidine is a potent analgesic (Cucchiaro et al. 2008) , with limited abuse liability as indicated by both weak positive reinforcing effects (Paterson et al. 2010 ) and the lack of locomotor sensitization seen in the present study. Sazetidine may also have potential as an aid for smoking cessation and alcohol abuse, as indicated by data showing that sazetidine can reduce nicotine and ethanol self administration Rezvani et al. 2010) . These findings suggest that sazetidine-like molecules may have advantages over traditional antidepressants by treating pain as well as nicotine and alcohol dependence.
Sazetidine's activity in the forced swim test is dependent on heteromeric nAChRs as shown by blockade with mecamylamine and DHβE (Harvey et al. 1996) , but not by the α7 antagonist MLA. The role of β2* nAChRs was confirmed by our results showing that sazetidine was inactive in β2 KO mice, although WT mice exhibited the expected antidepressant-like response. Ex vivo receptor occupancy studies showed a high correspondence between β2* receptor occupancy and potency of sazetidine in the forced swim test. Specifically, sazetidine was inactive in the forced swim test at 0.3 mg/kg and showed very low receptor occupancy at this dose (<10%). In contrast, doses of sazetidine that produced robust behavioral activity in the forced swim test also produced high levels of occupancy at β2* nAChRs (∼40% at 1 mg/kg and ∼90% at 3 mg/kg, 30 m post-drug administration). These results suggest that ∼10-40% of β2* receptor occupancy is required upon initial exposure of sazetidine to achieve behavioral efficacy in the forced swim test.
The behavioral actions of sazetidine were short (4 h) compared to its receptor occupancy profile (up to 8 h for the 1 mg/kg dose and up to 24 h for the 3 mg/kg dose), but long in comparison to its pharmacokinetic profile (brain and plasma levels were not detectable by 30 min). This dissociation appears to be a common feature among β2* nAChR agonists and partial agonists as both 5-I-A85380 and varenicline also showed prolonged β2* nAChR binding compared to their duration of action in the forced swim test. Sazetidine produced the longest β2* receptor occupancy (dissociation half-life of ∼8-24 h) in contrast to varenicline and 5-I-A85380 (dissociation half-life of ∼3-5 h). Despite prolonged β2* receptor occupancy, repeated sazetidine administration did not diminish the behavioral response in the forced swim test, demonstrating that sazetidine does not produce tolerance.
Several hypotheses might explain the dissociation between sazetidine's duration of action, pharmacokinetics, and receptor occupancy. First, sazetidine may directly mediate the antidepressant-like effect in the forced swim as sazetidine has high affinity for the β2* nAChR (K i = 0.2 nM) so that low levels of sazetidine, undetectable in whole brain by HPLC, could be sufficient to produce high receptor occupancy. Second, the behavioral actions of sazetidine could be mediated by an active metabolite that binds to β2* nAChRs, although our preliminary analysis detected no potential metabolites present at high levels in the brain (data not shown). Third, the discordance could be explained by desensitization (Ke et al. 1998; Reitstetter et al. 1999) , but this explanation is not supported by our current findings that suggest an activation mechanism mediates behavioral efficacy. Finally, sazetidine-induced activation of downstream signaling molecules could mediate antidepressant efficacy.
The results of the present study suggest that β2* nAChR activation is required for sazetidine's antidepressant-like activity in the forced swim test as pretreatment with nAChRs antagonists mecamylamine or DHβE completely blocked sazetidine's behavioral activity. As sazetidine is also a potent desensitizer in vitro (Xiao et al. 2006; Zwart et al. 2008) , it is possible that activation followed by sustained desensitization is critical to the long lasting antidepressant-like effects of sazetidine. However, our finding that a challenge dose of sazetidine given 7.5 h following the initial dose is equally efficacious as a single dose of sazetidine in the forced swim test, suggests that the nAChRs are not desensitized by the initial dose of sazetidine.
There is much evidence to support the hypothesis that blockade of nAChR is responsible for the antidepressant action of nicotinic ligands (Mineur and Picciotto 2010; Shytle et al. 2002) . Clinical studies have shown that the cholinesterase inhibitor, physostigmine, produces depressive symptoms in humans (Janowsky et al. 1972 ) and that mecamylamine (George et al. 2008 ) and the muscarinic antagonist scopolamine (Drevets and Furey 2010; Furey and Drevets 2006) relieve depressive symptoms in humans. Preclinical studies provide additional support for the hypothesis that increased cholinergic activity leads to depressed mood states. Flinders sensitive rats, a line selectively bred for increased cholinergic sensitivity, exhibit several depressive-like behaviors (Overstreet 1986; Pucilowski et al. 1993 ).
Although the current findings, which suggest that sazetidine's antidepressant effects are mediated by activation of nAChRs, appear in contrast to previous literature, it is possible that nAChR agonists and antagonists may both exert antidepressant action, but through independent mechanisms (Andreasen and Redrobe 2009a, b) . For example, both nicotine and mecamylamine have been shown to increase 5-HT release but presumably through distinct mechanisms (Kenny et al. 2000) . Sazetidine may produce antidepressantlike effects by increasing NE and DA (Zwart et al. 2008) , an effect that typically is not induced by nAChR antagonists.
Furthermore, a balance of activation and inactivation in different brain regions may be critical in mediating the antidepressant effects of nicotinic ligands (Mineur and Picciotto 2010) . Finally, various mouse strains or species may be differentially sensitive to detect nAChR agonist or antagonist mediated antidepressant-like responses. For example, the C57 mouse strain is sensitive to the antidepressantlike effects of mecamylamine (Caldarone et al. 2004; Rabenstein et al. 2006 ) and varenicline (Rollema et al. 2009 ), whereas the BALB strain was insensitive to both compounds in the present study. In addition, although mice show antidepressant-like responses to both nAChR agonists (Buckley et al. 2004 ) and antagonists (Andreasen et al. 2008; Andreasen and Redrobe 2009a,b; Caldarone et al. 2004; Lippiello et al. 2008; Mineur et al. 2007; Rabenstein et al. 2006) , rats tend to exhibit greater sensitivity to the antidepressant-like effect of agonists (e.g., nicotine) rather than antagonists (e.g., mecamylamine) (Djuric et al. 1999; Semba et al. 1998; Tizabi et al. 1999; Tizabi et al. 2000; Vieyra-Reyes et al. 2008) . It is likely that similar variations in responses to nicotinic agonists and antagonists will be observed in the human population.
These studies demonstrate that sazetidine's robust activity in a behavioral model of antidepressant efficacy is mediated by β2* nAChRs and that activation of a small population of non-occupied β2* nAChRs (10-40%) is sufficient to elicit full behavioral antidepressant-like responses. Thus, activation of β2* nAChRs may be a trigger mechanism for crucial downstream effects such as CREB that is critical for both nicotine-mediated conditioned reward (Brunzell et al. 2009 ) and antidepressant responsiveness (Carlezon et al. 2005 ). Understanding the mechanism by which nicotinic ligands such as sazetidine produce their antidepressant-like effects could lead to the development of novel antidepressants that could address unmet medical needs such as efficacy in treatment resistant populations.
